EUVIMEDEUVIMED entdecken
Crossref

Principles for Defining Estimands in Clinical Trials—A Proposal

Tobias Mütze iD, James Bell iD, Stefan Englert iD, Philip Hougaard iD, Dan Jackson iD, Vivian Lanius iD, Henrik Ravn iD

Pharmaceutical Statistics · 2025-01 · 24 (1)

DOI: 10.1002/pst.2432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 13.08.2024. Verfasst von Tobias Mütze und 6 weiteren Autor:innen. Beteiligte Einrichtung: Statistical Methodology, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Research Design. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ICH E9(R1) guideline outlines the estimand framework, which aligns planning, design, conduct, analysis, and interpretation of a clinical trial. The benefits and value of using this framework in clinical trials have been outlined in the literature, and guidance has been provided on how to choose the estimand and define the estimand attributes. Although progress has been made in the implementation of estimands in clinical trials, to the best of our knowledge, there is no published discussion on the basic principles that estimands in clinical trials should fulfill to be well defined and consistent with the ideas presented in the ICH E9(R1) guideline. Therefore, in this Viewpoint article, we propose four key principles for defining an estimand. These principles form a basis for well‐defined treatment effects that reflect the estimand thinking process. We hope that this Viewpoint will complement ICH E9(R1) and stimulate a discussion on which fundamental properties an estimand in a clinical trial should have and that such discussions will eventually lead to an improved clarity and precision for defining estimands in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicResearch DesignHumansData Interpretation, StatisticalGuidelines as Topic

Stichwörter der Autor:innen

ICH E9 (R1) addendumcausalityclinical question of interestestimands

Autor:innen und Institutionen

  • Statistical Methodology, Novartis Pharma AG, Basel, Switzerland.
  • Clinical Operations, Elderbrook Solutions GmbH, Buckinghamshire, UK.
  • Statistical Modeling and Methodology, Janssen-Cilag GmbH, Johnson & Johnson Company, Neuss, Germany.
  • Biostatistics and Data Science, H. Lundbeck A/S, Valby, Denmark.
  • Statistical Innovation, AstraZeneca, Cambridge, UK.
  • Clinical Statistics and Analytics, Bayer AG, Wuppertal, Germany.

ORCID-Profile: Tobias Mütze, James Bell, Stefan Englert, Philip Hougaard, Dan Jackson, Vivian Lanius, Henrik Ravn

Zitieren

APA

Mütze, T., Bell, J., Englert, S., Hougaard, P., Jackson, D., Lanius, V., & Ravn, H. (2025). Principles for Defining Estimands in Clinical Trials—A Proposal. Pharmaceutical Statistics, 24(1). https://doi.org/10.1002/pst.2432

Vancouver

Mütze T, Bell J, Englert S, Hougaard P, Jackson D, Lanius V, et al. Principles for Defining Estimands in Clinical Trials—A Proposal. Pharmaceutical Statistics. 2025;24(1). doi:10.1002/pst.2432

BibTeX
@article{Mtze2025,
  author = {Mütze, Tobias and Bell, James and Englert, Stefan and Hougaard, Philip and Jackson, Dan and Lanius, Vivian and Ravn, Henrik},
  title = {Principles for Defining Estimands in Clinical Trials—A Proposal},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  volume = {24},
  number = {1},
  doi = {10.1002/pst.2432}
}
Kostenlos starten →